Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Thoracic 1Head & Neck 1Gynecologic 1Dermatologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 21Lung Neoplasms 12Prostatic Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Stomach Neoplasms 4Prostatic Neoplasms, Castration-Resistant 4Breast Neoplasms 4Neoplasms 3Neoplasm Metastasis 3Endometrial Neoplasms 3Carcinoma, Transitional Cell 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Melanoma 2Lymphoid Interstitial Pneumonia 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Carcinoma 2Anatomic Stage I Breast Cancer AJCC v8 2Vaccinia 1Uterine Cervical Neoplasms 1Tongue Neoplasms 1Solid Tumors 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Oropharyngeal Neoplasms 1Non-small Cell Lung Cancer Metastatic 1

Interventions

pembrolizumab 7Nivolumab 6enfortumab vedotin 5Specimen Handling 5Magnetic Resonance Spectroscopy 5Ipilimumab 4sacituzumab govitecan 3Gemcitabine 3Docetaxel 3CTLA-4 Antigen 3cabozantinib 2Taxes 2Paclitaxel 2Cisplatin 2Carboplatin 2temsirolimus 1relatlimab 1lenvatinib 1eribulin 1avelumab 1atezolizumab 1Valproic Acid 1Sirolimus 1Single Person 1Radiosurgery 1Platinum 1Immunoglobulin G 1Disulfides 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × Docetaxel × 30 days × Clear all
NCT04895709 2026-06-04

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

Bristol-Myers Squibb

Phase 1/2 Recruiting
1,109 enrolled
BreastDermatologicGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT06524544 2026-06-02

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

National Cancer Institute (NCI)

Phase 3 Recruiting
320 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT04579224 2026-05-29

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
184 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡